Physician profile
Shane Christopher Tipton
NPI 1114321775
$1,637.63
in general payments reported to CMS, 2019-2025
15 companies · $803 in 2025
The $803 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.66 · 2022: $51.82 · 2023: $101 · 2024: $643 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $290.96 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $241.70 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $191.96 | 2024-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $171.05 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $150.15 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $147.69 | 2025 | Auvelity |
| Alkermes, INC. | $140.95 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Bausch Health US, LLC | $81.57 | 2024-2025 | Wellbutrin, Aplenzin |
| Tris Pharma INC | $52.62 | 2024 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $45.49 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $36.00 | 2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $32.07 | 2024 | Qelbree |
| Abbvie INC. | $20.77 | 2025 | |
| Noven Therapeutics, LLC | $20.29 | 2023 | Secuado |
| Indivior INC. | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Tipton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.